Pharmacopoeial Standards | News

New Primary Standards to support BP 2025 monographs

November 2024

The British Pharmacopoeia has released 11 new, high-quality BP primary standards to help assure the quality of medicines for patients globally, across a range of therapeutic classes.

Cardiovascular events, including heart attacks and strokes, remain a leading cause of morbidity and mortality worldwide. According to the World Health Organization (WHO) in June 2021, cardiovascular events account for an estimated 17.9 million deaths annually, representing 31% of all global deaths.

The use of medications like clopidogrel and doxazosin plays a significant role in reducing and preventing these events. Clopidogrel, an antiplatelet agent, prevents blood clots by inhibiting platelet aggregation, thereby reducing the risk of heart attacks and strokes, especially in patients with a history of cardiovascular disease. Doxazosin, an alpha-blocker, helps manage hypertension, a major risk factor for cardiovascular events, by relaxing blood vessels and improving blood flow. Together, these medications contribute to better cardiovascular health and lower the incidence of severe cardiovascular complications.

To view a standard directly in our shop, click on the item numbers in the downloadable document below.

New BP reference standards

November 2023

BP has just released 14 new, high-quality BP primary standards to help assure the quality of medicines for patients globally, across a range of therapeutic classes. To view a standard directly in our shop, click on the item numbers in the document below.